BioLife Solutions, Inc.
BLFS
$21.90
$0.914.34%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.44% | -37.00% | -49.42% | -52.53% | -53.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.44% | -37.00% | -49.42% | -52.53% | -53.11% |
| Cost of Revenue | -4.48% | -66.40% | -75.11% | -72.28% | -72.21% |
| Gross Profit | 16.85% | 6.06% | -5.54% | -17.98% | -15.05% |
| SG&A Expenses | -10.40% | -27.32% | -27.75% | -23.19% | -19.14% |
| Depreciation & Amortization | -22.24% | -62.13% | -62.91% | -63.45% | -63.71% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.93% | -48.00% | -52.98% | -50.08% | -49.61% |
| Operating Income | 72.19% | 84.42% | 66.15% | 39.67% | 35.35% |
| Income Before Tax | 38.15% | 97.97% | 79.06% | 90.42% | 87.25% |
| Income Tax Expenses | -58.33% | -212.90% | 100.51% | 100.12% | 99.52% |
| Earnings from Continuing Operations | 38.27% | 98.15% | 78.89% | 90.12% | 86.81% |
| Earnings from Discontinued Operations | 82.25% | -100.57% | -514.67% | -912.84% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.32% | 53.44% | 10.06% | 55.85% | 51.36% |
| EBIT | 72.19% | 84.42% | 66.15% | 39.67% | 35.35% |
| EBITDA | 108.68% | 113.29% | 88.31% | 48.00% | 40.29% |
| EPS Basic | 71.38% | 55.89% | 13.74% | 57.33% | 52.63% |
| Normalized Basic EPS | 72.99% | 84.75% | 66.26% | 40.67% | 36.11% |
| EPS Diluted | 70.72% | 55.89% | 13.74% | 57.33% | 52.63% |
| Normalized Diluted EPS | 72.83% | 84.75% | 66.26% | 40.67% | 36.11% |
| Average Basic Shares Outstanding | 5.37% | 5.56% | 4.61% | 3.71% | 2.91% |
| Average Diluted Shares Outstanding | 6.16% | 5.56% | 4.61% | 3.71% | 2.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
